These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clarithromycin in the treatment of community-acquired lower respiratory tract infections.
    Author: Anderson G.
    Journal: J Hosp Infect; 1991 Sep; 19 Suppl A():21-7. PubMed ID: 1684979.
    Abstract:
    Clarithromycin is a macrolide with in-vitro activity against the organisms usually responsible for community-acquired pneumonia and acute exacerbations of chronic bronchitis. Three double-blind controlled studies each in pneumonia and chronic bronchitis are reviewed. In pneumonia clarithromycin is as effective as erythromycin and in acute-on-chronic bronchitis is as effective as ampicillin. In an open study of 46 patients with pneumonia due to Legionella pneumophila, resolution occurred in 93% with no deaths. The incidence of adverse events was 20% in 3437 patients. These were rarely severe. Clarithromycin is better tolerated than erythromycin and its twice daily dosage is likely to lead to better patient compliance.
    [Abstract] [Full Text] [Related] [New Search]